



AION THERAPEUTIC INC.

**Unaudited Condensed Interim Consolidated
Financial Statements**

**For the Three and Six Months Ended
October 31, 2023 and 2022**

AION THERAPEUTIC INC.

Table of Contents

Table of Contents	1
Notice to Reader	2
Condensed Interim Consolidated Statements of Financial Position	3
Condensed Interim Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)	4
Condensed Interim Consolidated Statement of Changes in Shareholders' Deficiency	5
Condensed Interim Consolidated Statements of Cash Flows	6
Notes to the Condensed Interim Consolidated Financial Statements	7 - 20

AION THERAPEUTIC INC.

NOTICE TO READER

Under National Instrument 51-102 "Continuous Disclosure Obligations", Part 4, Subsection 4.3(3a), if an auditor has not performed a review of the condensed interim financial statements, they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed interim consolidated financial statements of the Company have been prepared by and are the responsibility of the Company's management. The Company's independent auditor has not performed a review of these unaudited condensed interim consolidated financial statements.

January 2, 2024

Aion Therapeutic Inc.

Condensed Interim Consolidated Statements Financial Position

As at October 31, 2023 and April 30, 2023

(Unaudited - Expressed in Canadian Dollars)

	Notes	October 31, 2023	April 30, 2023
Assets			
Current assets:			
Cash		\$ 926	\$ 336
Harmonized sales tax receivable		24,440	197,381
Deferred costs	15	18,522	-
Prepaid expenses		1,750	-
Loans and advances	13	271,264	-
		<u>316,902</u>	<u>197,717</u>
Equity investments	10	12,955	12,955
Total assets		<u>\$ 329,857</u>	<u>\$ 210,672</u>
Liabilities and shareholders' deficiency			
Current liabilities:			
Accounts payable and accrued liabilities		\$ 1,980,375	\$ 1,966,198
Loans payable	6	1,039,196	970,300
		<u>3,019,571</u>	<u>2,936,498</u>
Shareholders' deficiency			
Share capital	7	15,430,095	14,787,595
Contributed surplus		391,486	391,486
Warrant reserve		653,404	653,404
Share-based payment reserve		1,597,354	1,597,354
Share subscriptions received in advance		-	100,000
Accumulated other comprehensive income (loss)		(174,913)	(178,464)
Accumulated deficit		<u>(20,587,140)</u>	<u>(20,077,201)</u>
Total shareholders' deficiency		<u>(2,689,714)</u>	<u>(2,725,826)</u>
Total liabilities and shareholders' deficiency		<u>\$ 329,857</u>	<u>\$ 210,672</u>
Nature of Operations and Going Concern	1		
Subsequent Events	17		

Approved by the Board of Directors on January 2, 2024

"Graham Simmonds" (signed), Director"Paul Crath" (signed), Director

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Aion Therapeutic Inc.

Condensed Interim Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)

For the Three and Six Months Ended October 31, 2023 and 2022

(Unaudited - Expressed in Canadian Dollars)

	Notes	Three months ended October 31, 2023	Three months ended October 31, 2022 (Restated - Note 16)	Six months ended October 31, 2023	Six months ended October 31, 2022 (Restated - Note 16)
Expenses					
Accretion		\$ -	\$ 983	\$ -	\$ 2,051
Amortization of right-of-use assets		-	5,791	-	11,339
Consulting fees		122,419	73,677	190,946	146,341
Foreign exchange loss (gain)		(123,601)	(141,759)	8,161	(128,779)
Insurance		29,800	31,186	62,200	69,106
Interest expense		39,265	38,978	70,781	73,753
Interest income		(8,700)	-	(8,700)	-
Investor relations		-	20,000	-	35,000
Management fees	8	60,000	60,000	120,000	134,500
Office, administration and miscellaneous		21,603	2,585	21,868	2,764
Professional fees		34,072	13,675	34,072	133,675
Rent		1,200	1,842	1,800	3,056
Transfer agent and regulatory fees		5,301	18,622	8,811	23,352
		<u>(181,359)</u>	<u>(125,580)</u>	<u>(509,939)</u>	<u>(506,158)</u>
Reversal of impairment of intangible assets	5	-	-	-	111,659
Gain on settlement of debt	5, 7(c)	-	-	-	562,236
Net income (loss) for the period		<u>\$ (181,359)</u>	<u>\$ (125,580)</u>	<u>\$ (509,939)</u>	<u>\$ 167,737</u>
Income (loss) per share – basic		<u>\$ (0.001)</u>	<u>\$ (0.001)</u>	<u>\$ (0.003)</u>	<u>\$ 0.001</u>
Income (loss) per share – diluted		<u>\$ (0.001)</u>	<u>\$ (0.001)</u>	<u>\$ (0.003)</u>	<u>\$ 0.001</u>
Weighted average number of common shares outstanding – basic		190,318,291	147,299,269	168,808,780	145,505,791
Weighted average number of common shares outstanding – diluted		190,318,291	147,299,269	168,808,780	175,367,065
Net income (loss) for the period		<u>\$ (181,359)</u>	<u>\$ (125,580)</u>	<u>\$ (509,939)</u>	<u>\$ 167,737</u>
Foreign exchange translation adjustment		<u>(175,395)</u>	<u>(184,245)</u>	<u>3,551</u>	<u>(199,018)</u>
Comprehensive income (loss) for the period		<u>\$ (356,754)</u>	<u>\$ (309,825)</u>	<u>\$ (506,388)</u>	<u>\$ (31,281)</u>

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Aion Therapeutic Inc.

Condensed Interim Consolidated Statement of Changes in Shareholders' Deficiency

For the Six Months Ended October 31, 2023 and 2022

(Unaudited - Expressed in Canadian Dollars)

	Number of Common Shares Outstanding	Share Capital	Subscriptions Received in Advance	Contributed Surplus	Warrant Reserve	Share-based Compensation Reserve	Accumulated Deficit (Restated – Note 16)	Accumulated Other Comprehensive Income (Loss) (Restated – Note 16)	Shareholders' Equity (Deficiency) (Restated – Note 16)
Balance as of April 30, 2022	141,799,269	\$ 14,705,095	\$ -	\$ 391,486	\$ 653,404	\$ 1,597,354	\$ (19,820,543)	\$ 66,595	\$ (2,406,609)
Shares issued for settlement (Note 7(c))	5,500,000	82,500	-	-	-	-	-	-	82,500
Share subscriptions received	-	-	100,000	-	-	-	-	-	100,000
Foreign currency translation	-	-	-	-	-	-	-	(199,018)	(199,018)
Net income for the period (restated - Note 16)	-	-	-	-	-	-	167,737	-	167,737
Balance as at October 31, 2022	147,299,269	\$ 14,787,595	\$ 100,000	\$ 391,486	\$ 653,404	\$ 1,597,354	\$ (19,652,806)	\$ (132,423)	\$ (2,255,390)
Balance as of April 30, 2023	147,299,269	\$ 14,787,595	\$ 100,000	\$ 391,486	\$ 653,404	\$ 1,597,354	\$ (20,077,201)	\$ (178,464)	\$ (2,725,826)
Issuance of units on private placement (Note 7(c))	64,250,000	642,500	(100,000)	-	-	-	-	-	542,500
Foreign currency translation	-	-	-	-	-	-	-	3,551	3,551
Net loss for the period	-	-	-	-	-	-	(509,939)	-	(509,939)
Balance as at October 31, 2023	211,549,269	\$ 15,430,095	\$ -	\$ 391,486	\$ 653,404	\$ 1,597,354	\$ (20,587,140)	\$ (174,913)	\$ (2,689,714)

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Aion Therapeutic Inc.
Condensed Interim Consolidated Statements of Cash Flows
For the Six Months Ended October 31, 2023 and 2022
(Unaudited - Expressed in Canadian Dollars)

	Six Months Ended October 31, 2023	Six Months Ended October 31, 2022 (Restated - Note 16)
Cash flows from operating activities		
Net income (loss) for the period	\$ (509,939)	\$ 167,737
Items not involving cash:		
Accretion on lease obligation	-	2,051
Accrued interest payable	68,896	71,646
Accrued interest receivable	(5,204)	-
Amortization of right-of-use assets	-	11,339
Reversal on impairment of intangible asset	-	(111,659)
Gain on settlement of debt	-	(562,236)
Non-cash working capital adjustments		
Harmonized sales tax receivable	172,941	(29,123)
Deferred costs	(18,522)	-
Prepaid expenses	(1,750)	(21,258)
Accounts payable and accrued liabilities	14,177	398,314
Total cash used in operating activities	(279,401)	(73,189)
Cash flows from investing activities		
Loans and advances	(266,060)	-
Total cash used in investing activities	(266,060)	-
Cash flows from financing activities		
Shares subscription received	-	100,000
Proceeds from private placement	542,500	-
Repayment of lease obligations	-	(12,524)
Proceeds from loans payable	-	218,205
Repayment of loans payable	-	(20,000)
Total cash provided by financing activities	542,500	285,681
Effect of foreign currency exchange rate changes	3,551	(199,018)
Total increase in cash during the period	590	13,474
Cash and cash equivalents - beginning of period	336	-
Cash and cash equivalents - end of period	\$ 926	\$ 13,474

The following are non-cash transactions affecting cash flows from investing and financing activities during the six months ended October 31, 2023:

- The Company issued 21,375,000 Warrants in connection with a private placement (Note 7(c)); and
- The Company issued 10,750,000 Warrants in connection with a private placement (Note 7(c)).

The following are non-cash transactions affecting cash flows from investing and financing activities during the six months ended October 31, 2022:

- The Company issued 5,500,000 common shares valued at \$82,500 on settlement of debt; and
- The Company received equity investments valued at \$121,763 on sale of patents.

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Aion Therapeutic Inc.

Notes to the Condensed Interim Consolidated Financial Statements
For the Three and Six Months Ended October 31, 2023 and 2022
(Unaudited - Expressed in Canadian Dollars)

1. NATURE OF OPERATIONS AND GOING CONCERN

Aion Therapeutic Inc. ("Aion" or the "Company") was incorporated on January 13, 2011 under the *Business Corporations Act* (British Columbia). The Company's registered office is located at 700 West Georgia Street, Suite 2200, Vancouver, BC, V7Y 1K8. The Company is publicly traded on the Canadian Securities Exchange under the symbol "AION".

The Company is a forward-thinking business within the health and wellness sector with a diverse portfolio of intellectual property. With a commitment to innovation and transformative solutions, the Company is poised to drive positive change to redefine the boundaries of health and wellness.

These condensed interim consolidated financial statements have been prepared using International Financial Reporting Standards ("IFRS") on a going concern basis, which presumes the realization of assets and discharge of liabilities in the normal course of business, for the next fiscal year. As at October 31, 2023, the Company had cash of \$926 (April 30, 2023 - \$336), working capital deficit of \$2,702,669 (April 30, 2023 - \$2,738,781), and an accumulated deficit of \$20,587,140 (April 30, 2023 - \$20,077,201). The continuing operations of the Company are dependent on funding. The Company intends to finance its future requirements through a combination of debt and/or equity issuance. There is no assurance that the Company will be able to obtain such financings or obtain them on favorable terms. This uncertainty may cast significant doubt about the ability of the Company to continue as a going concern. These condensed interim consolidated financial statements do not include any adjustments to the carrying value or presentation of assets or liabilities that might be necessary should the Company be unable to continue as a going concern. These adjustments could be material.

Aion Therapeutic Inc.

Notes to the Condensed Interim Consolidated Financial Statements
For the Three and Six Months Ended October 31, 2023 and 2022
(Unaudited - Expressed in Canadian Dollars)

2. BASIS OF PRESENTATION

Basis of preparation

These condensed interim consolidated financial statements have been prepared on the historical cost basis except for certain financial instruments which are measured at fair value. In addition, these condensed interim consolidated financial statements have been prepared using the accrual basis of accounting, except for certain cash flow information. The functional currency for the Company, Oservco Management Corp., 1160516 B.C. Ltd., Bare Root Production Osoyoos Inc., and 1196691 B.C. Ltd. d/b/a "PCAI Pharma" have been determined to be the Canadian dollar. The functional currency of AI Pharmaceuticals Jamaica Limited ("AI Pharma") has been determined to be the Jamaican dollar.

Statement of compliance

These condensed interim consolidated financial statements have been prepared in conformity with International Accounting Standards ("IAS") 34 – *Interim Financial Reporting* and do not include all information required for full annual consolidated financial statements in accordance with IFRS and should be read in conjunction with the audited consolidated financials for the year ended April 30, 2023. These condensed interim consolidated financial statements of the Company and its subsidiaries were prepared using accounting policies consistent with IFRS as issued by the International Accounting Standards Board and interpretations of the IFRS Interpretations Committee ("IFRIC").

These condensed interim consolidated financial statements were authorized for issuance by the Board of Directors on January 2, 2024.

Basis of consolidation

Subsidiaries are entities controlled by the Company. Control exists when the Company has the power, directly and indirectly, to govern the financial and operating policies of an entity and be exposed to the variable returns from its activities. The financial statements of the Company's subsidiaries are included in the condensed interim consolidated financial statements from the date that control commences until the date that control ceases. These condensed interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries: Oservco Management Corp., 1160516 B.C. Ltd. and its wholly owned subsidiary Bare Root Production Osoyoos Inc., and PCAI Pharma and its wholly-owned subsidiary AI Pharma. All inter-company transactions and balances have been eliminated on consolidation.

Significant accounting judgments and estimates

The preparation of these condensed interim consolidated financial statements in compliance with IFRS requires management to make certain critical accounting estimates and assumptions. These estimates and assumptions affect the reported amounts of assets, liabilities, shareholders' equity (deficiency) and the disclosure of contingent assets and liabilities, as at the date of the condensed interim consolidated financial statements, and expenses for the periods reported.

Aion Therapeutic Inc.

Notes to the Condensed Interim Consolidated Financial Statements
For the Three and Six Months Ended October 31, 2023 and 2022
(Unaudited - Expressed in Canadian Dollars)

2. BASIS OF PRESENTATION (continued)

Significant accounting judgments and estimates (continued)

Critical Judgements

The preparation of these condensed interim consolidated financial statements requires management to make judgements regarding the going concern of the Company, as previously discussed in Note 1, as well as the determination of functional currency. The functional currency is the currency of the primary economic environment in which an entity operates and has been determined for each entity within the Company. The functional currency for the Company, Oservco Management Corp., 1160516 B.C. Ltd., Bare Root Production Osoyoos Inc., and PCAI Pharma have been determined to be the Canadian dollar. The functional currency of AI Pharma has been determined to be the Jamaican dollar.

Key Sources of Estimation Uncertainty

Because a precise determination of many assets and liabilities is dependent upon future events, the preparation of financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates and such differences could be significant.

Significant estimates made by management affecting the condensed interim consolidated financial statements include:

Share-based payments

Estimating fair value for granted stock options and warrants requires determining the most appropriate valuation model which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life of the option or warrant, volatility, dividend yield, and rate of forfeitures and making assumptions about them.

Discount rates used in convertible debentures

The Company calculates the liability portion of convertible debentures by calculating the present value of the debenture and related interest, using a discount rate equal to the market rate that would be given for similar debt, without a conversion feature. Management determines this rate by assessing what rate the Company could borrow funds at from an unrelated party.

Deferred tax assets and liabilities

The estimation of income taxes includes evaluating the recoverability of deferred tax assets and liabilities based on an assessment of the Company's ability to utilize the underlying future tax deductions against future taxable income prior to expiry of those deductions. Management assesses whether it is probable that some or all of the deferred income tax assets and liabilities will not be realized. The ultimate realization of deferred tax assets and liabilities is dependent upon the generation of future taxable income, which in turn is dependent upon the successful execution of the Company's business plan. To the extent that management's assessment of the Company's ability to utilize future tax deductions changes, the Company would be required to recognize more or fewer deferred tax assets or liabilities, and deferred income tax provisions or recoveries could be affected.

Aion Therapeutic Inc.

Notes to the Condensed Interim Consolidated Financial Statements
For the Three and Six Months Ended October 31, 2023 and 2022
(Unaudited - Expressed in Canadian Dollars)

2. BASIS OF PRESENTATION (continued)

Significant accounting judgments and estimates (continued)

Impairment of tangible assets

The Company assesses the carrying value of its tangible assets annually or more frequently if warranted by a change in circumstances. If it is determined that the carrying values of assets cannot be recovered, the unrecoverable amounts are charged against current net income (loss). Recoverability is dependent upon assumptions and judgements regarding market conditions, costs of operations and sustaining capital requirements. Other assumptions used in the calculation of recoverable amounts are discount rates, and future cash flows. A material change in the assumptions may significantly impact the potential impairment of these assets.

Leases

The Company estimates the lease term by considering the facts and circumstances that can create an economic incentive to exercise an extension option, or not exercise a termination option by assessing relevant factors such as store profitability. Extension options (or periods after termination options) are only included in the lease term if the lease is reasonably certain to be extended (or not terminated). The assessment of the lease term is reviewed if a significant event or a significant change in circumstance occurs, which affects this assessment and that is within the control of the lessee. The Company estimates the incremental borrowing rate used to measure our lease liability for each lease contract. This includes estimation in determining the asset-specific security impact.

Contingencies

By their nature, contingencies will only be resolved when one or more future events occur or fail to occur. The assessment of contingencies inherently involves the exercise of significant judgment and estimates of the outcome of future events.

Capitalization of development costs

Initial capitalization of development costs is based on management's judgment that technical and economic feasibility is confirmed. An intangible asset arising from development is recognized if the Company can demonstrate all of the following:

- a) the technical feasibility of completing the intangible asset so that it will be available for use or sale;
- b) its intention to complete the intangible asset and use or sell it;
- c) its ability to use or sell the intangible asset;
- d) how the intangible asset will generate probable, future economic benefits;
- e) the availability of adequate technical, financial and other resources; and
- f) its ability to measure reliably the expenditure attributable to the intangible asset during its development phase.

Aion Therapeutic Inc.

Notes to the Condensed Interim Consolidated Financial Statements
For the Three and Six Months Ended October 31, 2023 and 2022
(Unaudited - Expressed in Canadian Dollars)

2. BASIS OF PRESENTATION (continued)

Significant accounting judgments and estimates (continued)

Impairment of intangible assets

The values associated with intangible assets involve significant estimates and assumptions, including discount rates and useful lives. At least annually, the carrying amount of intangible assets are reviewed for potential impairment. Among other things, this review considers the recoverable amounts of the intangible assets based on the higher of value in use or fair value less costs of disposal using discounted estimated future cash flows. These significant estimates require considerable judgment which could affect the Company's future results if the current estimates of future performance and fair value change.

3. SIGNIFICANT ACCOUNTING POLICIES

The accounting policies set out in the consolidated financial statements as of April 30, 2023 have been applied consistently to all periods presented in these condensed interim consolidated financial statements.

4. PROPERTY AND EQUIPMENT

The Company's property and equipment are comprised of the following:

		Equipment ^(a)		Total
<u>Cost</u>				
Balance at April 30, 2022 ^(b)	\$	-	\$	-
Reversal of impairment ^(c)		135,185		135,185
Sale of equipment ^(c)		(135,185)		(135,185)
Balance at April 30, 2023	\$	-	\$	-
Additions		-		-
Sale of equipment		-		-
Balance at October 31, 2023	\$	-	\$	-
<u>Net Book Value</u>				
Balance, October 31, 2023	\$	-	\$	-
Balance, April 30, 2023	\$	-	\$	-

- The equipment is comprised of two identical extraction systems (the "Extraction Systems"), which the Company acquired in 2019.
- As at April 30, 2022, the two Extraction Systems were fully impaired to \$nil due to no indication of a future economic benefit being generated.
- On January 31, 2023, the Company sold its fully impaired Extraction Systems for \$135,185, which proceeds were received directly by the promissory note holder (Note 6).

Aion Therapeutic Inc.

Notes to the Condensed Interim Consolidated Financial Statements
For the Three and Six Months Ended October 31, 2023 and 2022
(Unaudited - Expressed in Canadian Dollars)

5. INTANGIBLE ASSETS

The Company's intangible assets are comprised of the following:

	Intellectual Property	Patents	Total
Cost			
Balance at April 30, 2022	\$ -	\$ -	\$ -
Reversal of impairment on patents	-	111,659	111,659
Sale of patents	-	(111,659)	(111,659)
Balance at April 30, 2023	\$ -	\$ -	\$ -
Additions (disposals)	-	-	-
Impairment	-	-	-
Balance at October 31, 2023	\$ -	\$ -	\$ -
Net Book Value			
Balance, October 31, 2023 and April 30, 2023	\$ -	\$ -	\$ -

The Company's intangible assets relate to the development of intellectual property and development of a patent portfolio. During the year ended April 30, 2021, these intangible assets were fully impaired to \$nil due to lack of revenue from the AI Pharma.

On June 30, 2022, the Company entered into an asset purchase agreement (the "APA") with Apollon Formularies PLC ("Apollon"), a public company related by common director, pursuant to which the Company sold four patent applications, and all associated supporting data to Apollon (collectively, the "Intellectual Property"). In consideration for the Intellectual Property, Apollon issued to the Company an aggregate of 4,348,679 common shares in the capital of Apollon (Note 10). The Company recorded a reversal of impairment at \$111,659 and gain on the sale of \$10,104 during the year ended April 30, 2023.

6. LOANS PAYABLE

The Company had promissory notes, inclusive of accrued interest, outstanding in the amount of \$744,061 during the year ended April 30, 2022. During the year ended April 30, 2023, the Company entered into various promissory notes with non-arm's length parties for the principal amount of \$237,594. These promissory notes are unsecured, bear interest at 18% per annum and are due on demand. The Company repaid \$155,185 of these promissory notes during the year ended April 30, 2023, which included proceeds from the sale of equipment for \$135,185 received directly by the promissory note holder and applied against the principal amount of the promissory notes (Note 4).

The Company did not enter into any promissory notes during the six months ended October 31, 2023.

Interest expense in the amount of \$68,896 was recorded for the six months ended October 31, 2023 (October 31, 2022 – \$71,646). As at October 31, 2023, the outstanding loans payable including accrued interest amounted to \$1,039,196 (April 30, 2023 – \$970,300).

Aion Therapeutic Inc.

Notes to the Condensed Interim Consolidated Financial Statements
For the Three and Six Months Ended October 31, 2023 and 2022
(Unaudited - Expressed in Canadian Dollars)

7. SHARE CAPITAL

The Company is authorized to issue the following shares:

- Unlimited Class “A” voting common shares with no par value
- Unlimited Class “B” non-voting preferred shares with a par value of \$1.00
- Unlimited Class “C” voting common shares with no par value

a) Common shares

The holders of common shares are entitled to receive dividends which are declared from time to time and are entitled to one vote per share at meetings of the Company. All shares are ranked equally with regard to the Company's residual assets.

As at October 31, 2023, the Company had 211,549,269 (April 30, 2023 – 147,299,269) Class A common shares issued and outstanding. There were no issuances of Class C common shares during the six months ended October 31, 2023 and year ended April 30, 2023.

b) Preferred shares

The Company is authorized to issue an unlimited number of preferred shares with the rights, privileges and restrictions determined by the Board of Directors at the time of issuance.

There were no issuances of Class B non-voting preferred shares during the six months ended October 31, 2023 and year ended April 30, 2023.

c) Share issuances

Six months ended October 31, 2023

During the six months ended October 31, 2023, the Company completed two tranches of non-brokered private placements (each a “Private Placement”) through the issuance of units (“Units”) of the Company. Each Unit consisted of one common share and one-half of one common share purchase warrant (each whole warrant, a “Warrant”). Each Warrant entitles the holder thereof to purchase one common share for a period of eighteen months from the closing date at a price of \$0.10 per common share. The proceeds from the issuance of Units are allocated between share capital and warrants. The Company has adopted the residual method with respect to the measurement of the Warrants and accordingly the difference between the proceeds raised and the value of the common shares is the residual fair value of the Warrants. During the six month period ended October 31, 2023, the value to Warrants assigned for Private Placement was \$nil.

During the six months ended October 31, 2023, the Company issued the following common shares:

- On August 14, 2023, the Company closed a Private Placement and issued 42,750,000 Units of the Company, at a price of \$0.01 per Unit, for gross proceeds of \$427,500. Inclusive of the gross proceeds was the subscriptions received in the amount of \$100,000 during the year ended April 30, 2023. In connection with the issuance of the Units, the Company issued 42,750,000 common shares and 21,375,000 Warrants.
- On October 5, 2023, the Company closed a Private Placement and issued 21,500,000 Units of the Company, at a price of \$0.01 per Unit, for gross proceeds of \$215,000. In connection with the issuance of the Units, the Company issued 21,500,000 common shares and 10,750,000 Warrants.

Aion Therapeutic Inc.

Notes to the Condensed Interim Consolidated Financial Statements
For the Three and Six Months Ended October 31, 2023 and 2022
(Unaudited - Expressed in Canadian Dollars)

7. SHARE CAPITAL (continued)

Year ended April 30, 2023

On June 30, 2022, Dr. Stephen D. Barnhill resigned as a Director of the Company and from all subsidiary level appointments, and Dr. Herbert Fritsche resigned as Chief Science Officer of the Company. In connection with Dr. Barnhill's resignation, the Company issued an aggregate of 5,500,000 common shares valued at \$82,500 to settle all amounts owed by the Company and its subsidiaries to Dr. Barnhill. The Company recorded a gain of \$552,132 on this settlement.

d) Warrants

As at October 31, 2023, the Company had the following share purchase warrants issued and outstanding:

	Number of Warrants	Weighted Average Exercise Price (\$)
Outstanding, April 30, 2022	38,172,648	0.17
Expired	(28,661,848)	-
Outstanding, April 30, 2023	9,510,800	0.16
Issued	32,125,000	0.10
Expired	(8,735,800)	0.15
Outstanding, October 31, 2023	32,900,000	0.10

As at October 31, 2023, the Company had the following share purchase warrants outstanding:

Outstanding	Exercise Price (\$)	Remaining Life (Years)	Expiry Date
575,000	0.25	0.44	April 8, 2024
200,000	0.45	0.44	April 8, 2024
21,375,000	0.10	1.29	February 14, 2025
10,750,000	0.10	1.43	April 5, 2025
32,900,000	0.10	1.32	

e) Stock options

The Company did not grant any options during the three months ended July 31, 2023 and the year ended April 30, 2023.

As at October 31, 2023 and April 30, 2023, the Company had the following options issued and outstanding:

	Number of Options	Weighted Average Exercise Price (\$)
Outstanding, April 30, 2023	6,725,000	0.13
Expired	(2,725,000)	0.10
Cancelled	(2,250,000)	0.15
Outstanding, October 31, 2023	1,750,000	0.15

Aion Therapeutic Inc.

Notes to the Condensed Interim Consolidated Financial Statements
For the Three and Six Months Ended October 31, 2023 and 2022
(Unaudited - Expressed in Canadian Dollars)

7. SHARE CAPITAL (continued)

e) Stock options (continued)

A summary of outstanding and exercisable stock options is as follows:

Outstanding	Exercisable	Exercise Price (\$)	Remaining Life (Years)	Expiry Date
1,750,000	1,750,000	0.15	0.26	February 1, 2024

8. RELATED PARTY TRANSACTIONS

Key management personnel include the Chief Executive Officer (“CEO”), the Chief Financial Officer (“CFO”), the Board of Directors, close family members and enterprises that are controlled by such individuals as well as certain persons performing similar functions.

Transactions with key management personnel not disclosed elsewhere in these condensed interim Condensed Interim Consolidated financial statements include the following:

During the three and six months ended October 31, 2023, amounts expensed for key management services include the following:

	Three months ended October 31, 2023	Six months ended October 31, 2023
Fees for services of CEO	\$ 45,000	\$ 90,000
Fees for services of CFO	15,000	30,000
Fees for services of Director	-	-
Management fees	\$ 60,000	\$ 120,000

During the three and six months ended October 31, 2022, amounts expensed for key management services include the following:

	Three months ended October 31, 2022	Six months ended October 31, 2022
Fees for services of CEO	\$ 45,000	\$ 90,000
Fees for services of CFO	15,000	30,000
Fees for services of Director	-	14,500
Management fees	\$ 60,000	\$ 134,500

As at October 31, 2023, the Company had the following balances with related parties:

- Included in due from related parties is \$nil (April 30, 2023 - \$nil); and
- Included in accounts payable and accrued liabilities is \$214,700 (April 30, 2023 – \$283,500) due to related parties.

The right-of-use assets (Note 11), the lease obligations (Note 12), and repayment of lease obligation for \$nil (2022 – \$12,524) for the six months ended October 31, 2023, were paid to entities which are under common control with the Company.

Aion Therapeutic Inc.

Notes to the Condensed Interim Consolidated Financial Statements
For the Three and Six Months Ended October 31, 2023 and 2022
(Unaudited - Expressed in Canadian Dollars)

9. FINANCIAL INSTRUMENTS

The Company's financial instruments consist of cash, equity investments, loans and advances, accounts payable and loan payable.

The Company's cash and equity investment is measured at fair value under the fair value hierarchy based on level one quoted prices in active markets for identical assets or liabilities. The fair value of the Company's loans and advances, accounts payable and loans payable approximate their fair values due to their short-term nature.

The Company's financial instruments are exposed to certain financial risks, including currency risk, credit risk, liquidity risk, interest rate risk and price risk.

Financial risk management and objectives

The Company's activities expose it to a variety of financial risks: credit risk, liquidity risk, and market risk (including interest rate risk, foreign currency risk, and commodity price risk).

The Company thoroughly examines the various financial risks to which it is exposed and assesses the impact and likelihood of those risks. Where material, these risks are reviewed and monitored by the Board of Directors.

The Company's financial instruments are exposed to certain financial risks, including credit risk, liquidity risk, interest rate risk and market risk.

Credit risk

Credit risk is the risk of an unexpected loss if a customer or third party to a financial instrument fails to meet its contractual obligations. The Company is not exposed to significant credit risk.

Liquidity risk

Liquidity risk is the risk that the Company will not have sufficient cash resources to meet its financial obligations as they come due. The Company's liquidity and operating results may be adversely affected if its access to the capital market is hindered, whether as a result of a downturn in stock market conditions generally or matters specific to the Company. The Company generates cash flows primarily from its financing activities.

The Company manages its liquidity needs by carefully monitoring scheduled costs. Liquidity is measured in various time bands, on day to day and week-to-week basis, as well as on long term liquidity needs over 180 day to 360 day look out periods. Funding for long term liquidity needs is based on the ability of the Company to successfully complete private placements as well as, in certain cases, to pay the outstanding balances owed in shares of the Company rather than in cash.

As at October 31, 2023, the Company had cash and cash equivalents of \$926 and current liabilities of \$3,019,571.

The Company considers expected cash flow from financial assets in managing liquidity risk. The Company's existing cash resources currently do not meet the current cash outflow requirements. As a result, the Company is at risk of not being a going concern if management is unable to raise the appropriate funds prior to the maturity of the financial liabilities. Appropriate going concern disclosures have been made in Note 1.

Aion Therapeutic Inc.

Notes to the Condensed Interim Consolidated Financial Statements
For the Three and Six Months Ended October 31, 2023 and 2022
(Unaudited - Expressed in Canadian Dollars)

9. FINANCIAL INSTRUMENTS (continued)

Financial risk management and objectives (continued)

Market Risk

Market risk is the risk of loss that may arise from changes in market factors such as interest rates, commodity and equity prices, and foreign exchange rates.

(a) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is not exposed to significant interest rate risk as the terms of its loans payable are based on fixed interest rates.

(b) Price risk

The Company is exposed to significant price risk via its equity investment (Note 10), as this is based on the price in the quoted market.

(c) Currency risk

The Company is exposed to foreign currency risk from fluctuations in foreign exchange rates and the degree of volatility in these rates due to the timing of their accounts payable balances. This risk is mitigated by timely payment of creditors and monitoring of foreign exchange fluctuations by management. As at October 31, 2023 and April 30, 2023, the Company did not use derivative instruments to hedge its exposure to foreign currency risk.

10. EQUITY INVESTMENTS

On June 30, 2022, the Company entered into an asset purchase agreement (the "APA") with Apollon Formularies PLC ("Apollon"), a public Company controlled by common director, Dr. Stephen D. Barnhill. Pursuant to the APA, the Company sold four patent applications, and all associated supporting data to Apollon (collectively, the "Intellectual Property"). In consideration for the Intellectual Property, Apollon: (i) issued the Company an aggregate of 4,348,679 common shares in the capital of Apollon at a consideration of \$0.028 (£0.018) per common share; and (ii) agreed to pay the Company an indefinite royalty fee of 4% of the global net revenue generated by the Intellectual Property (the "Royalty"). The Royalty is payable quarterly in arrears, commencing upon the first commercial product sales utilizing the Intellectual Property. These patents were considered impaired and written off in the prior years. The Company reversed the impairment for patents for \$111,659 (Note 5) and recorded the investment in equity for \$121,763 with a \$10,104 gain on settlement.

As at the year ended April 30, 2023, these investments were measured at \$12,955 with an unrealized loss of \$108,808 recorded in the consolidated statement of loss and comprehensive loss.

Aion Therapeutic Inc.

Notes to the Condensed Interim Consolidated Financial Statements
For the Three and Six Months Ended October 31, 2023 and 2022
(Unaudited - Expressed in Canadian Dollars)

11. RIGHT-OF-USE ASSET

Balance, April 30, 2022	\$	-
Addition during the period		45,093
Amortization		(17,301)
Early termination of sub-leased premises		(28,511)
Foreign exchange adjustment		719
Balance, April 30, 2023 and October 31, 2023	\$	-

Right-of-use asset consisted of a sub-lease of commercial space in Jamaica amortized over 24 months. During the six months ended October 31, 2023, the Company amortized \$nil (October 31, 2022 –\$11,339) of its right-of-use asset. Effective January 31, 2023, the Company terminated the lease and recorded a net gain of \$1,059 during the year ended April 30, 2023.

12. LEASE LIABILITIES

At the commencement date of the leases, the lease liability was measured at the present value of the lease payments that were not paid at that date. The lease payments are discounted using an interest rate of 10% which is the Company's incremental borrowing rate. The effective interest rate is 10.47%. The continuity of the lease liabilities is presented in the table below:

Balance, April 30, 2022	\$	-
Addition during the period		45,093
Interest accretion expense		2,927
Lease payments made during the period		(19,160)
Early termination of sub-leased premises		(29,570)
Foreign exchange adjustment		710
Balance, April 30, 2023 and October 31, 2023	\$	-

13. LOANS AND ADVANCES

During the six months ended October 31, 2023, the Company advanced loans for \$266,060 (US \$200,000) to an arms-length party under various promissory notes. The promissory notes bear interest at 10% per annum and mature on October 31, 2023.

Interest income in relation to these loans and advances in the amount of \$5,204 was recorded for the six months ended October 31, 2023 (October 31, 2022 – \$nil). As at October 31, 2023, the outstanding loans receivable including accrued interest amounted to \$274,760 (April 30, 2023 – \$nil).

Aion Therapeutic Inc.

Notes to the Condensed Interim Consolidated Financial Statements
For the Three and Six Months Ended October 31, 2023 and 2022
(Unaudited - Expressed in Canadian Dollars)

14. CAPITAL MANAGEMENT

The Company's capital structure has been defined by management as being comprised of shareholders' equity. The Company's objectives when managing its capital structure are to preserve the Company's access to capital markets and its ability to meet its financial obligations and to finance its activities and general corporate costs. This is achieved by the Board of Directors review and acceptance of budgets that are achievable within existing resources made available from private placements or other funding.

The Company monitors its capital structure using annual forecasted cash flows, budgets and targets.

The Company currently has no source of revenue; as such, the Company is dependent upon external financing to fund its activities. In order to carry future projects and pay for administrative costs, the Company will spend its existing working capital and raise additional funds as needed. Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable.

Based on available funds, the Company manages its capital structure and makes adjustments to it to maintain flexibility while achieving the objectives stated above as well as support future business opportunities. To manage the capital structure the Company may adjust its operating expenditure plans, or issue new common shares and warrants.

The Board of Directors does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company's management to sustain future development of the business. The Company is not subject to externally imposed capital requirements or covenants.

15. SHARE PURCHASE AGREEMENT

On October 10, 2023, the Company entered into a definitive share purchase agreement (the "Purchase Agreement") with Toppen Health Inc. ("Toppen") and shareholders holding a majority of the issued and outstanding shares of Toppen (the "Toppen Shares"), a US-based innovative health and wellness company, dedicated to delivering state-of-the-art water filtration solutions (the "Acquisition").

The purchase price for the Acquisition is CAD \$10,000,000 (the "Purchase Consideration"). The Purchase Consideration shall be satisfied through the issuance of 200,000,000 common shares in the capital of the Company, to be issued at a deemed price of \$0.05 per share (the "Consideration Shares"). The Consideration Shares will be subject to a statutory resale restriction of four months and a day from the date of issuance and such further restrictions as may be apply under foreign securities laws, as well as the escrow requirements of the Canadian Securities Exchange ("CSE"). Furthermore, the Company may also be required to pay contingent consideration of US \$2,000,000 (the "Earn-Out Payment") if Toppen achieves revenue equal to or greater than US \$5,000,000 for the period from October 18, 2023 to April 30, 2025. Eligible revenue for the purposes of the earn-out calculation must exceed forty percent gross margins. The completion of the Acquisition was subject to the successful completion of the Company's due diligence review of Toppen, the approval of the Canadian Securities Exchange and other customary closing conditions. On December 15, 2023, the Acquisition was completed (Note 17).

As of October 31, 2023, the Company incurred legal costs of \$18,522, which have been capitalized as deferred costs.

Aion Therapeutic Inc.

Notes to the Condensed Interim Consolidated Financial Statements
For the Three and Six Months Ended October 31, 2023 and 2022
(Unaudited - Expressed in Canadian Dollars)

16. RESTATEMENT OF PRIOR PERIOD COMPARATIVE FINANCIAL STATEMENTS

The comparative condensed interim consolidated financial statements for the six months ended October 31, 2022 are restated to reflect the reversal of the impairment of intangible assets and adjustment to the gain on settlement of debt. There are no changes to the financial statements for the three months ended October 31, 2022. There are no changes to the total cash used in operating activities or total cash provided by financing activities for the six months ended October 31, 2022.

The effect of the changes in the comparative condensed interim consolidated financial statements is summarized as follows:

	For the Six Months Ended October 31, 2022	
	Prior to Restatement	Restated
	\$	\$
<u>Condensed Interim Consolidated Statements of Income (Loss) and Comprehensive Income (Loss):</u>		
Foreign exchange gain	140,412	128,779
Total operating loss	(494,525)	(506,158)
Reversal of impairment of intangible assets	-	111,659
Gain on settlement of debt	1,177,038	562,236
Net income for the period	682,513	167,737
Income per share-basic	0.005	0.001
Income per share-diluted	0.004	0.001
Comprehensive income (loss) for the period	483,495	(31,281)
<u>Condensed Interim Consolidated Statements of Cash Flows:</u>		
Net income for the period	682,513	167,737
Items not involving cash:		
Reversal of impairment of intangible assets	-	(111,659)
Gain on settlement of debt	(1,177,038)	(562,236)
Non-cash working capital adjustment:		
Accounts payable and accrued liabilities	386,681	398,314

17. SUBSEQUENT EVENTS

On December 15, 2023, the Company announced it had closed the Acquisition whereby the Company acquired all of the outstanding shares of Toppen. The Acquisition was completed pursuant to the Purchase Agreement dated October 10, 2023 (Note 15) with Toppen and shareholders holding a majority of the issued and outstanding shares of Toppen and a separate share purchase agreement with the remaining Toppen shareholders, entered into on the closing of the Acquisition. The Purchase Consideration was satisfied through the issuance of the Consideration Shares, being 200,000,000 common shares in the capital of the Company, issued at a deemed price of \$0.05 per share. The Company may also be required to pay the Earn-Out Payment of US \$2,000,000 if Toppen achieves revenue equal to or greater than US \$5,000,000 for the period from October 18, 2023 to April 30, 2025.